GALMED PHARMACEUTICALS LTD (GLMD) Stock News
NASDAQ:GLMD - Nasdaq - IL0011313900 - Common Stock - Currency: USD
GLMD Latest News, Press Relases and Analysis
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.
GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024
Galmed Pharmaceuticals just reported results for the first quarter of 2024.
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for fibroinflammatory...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth diving into on Wednesday morning to get ready for all of the hottest news moving shares today!
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
Explore three penny stocks primed for significant growth, backed by Strong Buy ratings from Wall Street. Play it high-risk.
GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023
GLMD stock results show that Galmed Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
/PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!
